Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$234.62
-2.4%
$238.68
$229.40
$287.32
$67.78B0.451.41 million shs1.72 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$72.86
+1.2%
$68.30
$48.35
$74.39
$108.05B0.776.66 million shs7.45 million shs
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$85.24
+0.2%
$90.13
$60.57
$96.12
$51.37B1.13.77 million shs2.33 million shs
Stryker Co. stock logo
SYK
Stryker
$328.45
+0.6%
$347.52
$249.98
$361.41
$124.27B0.911.33 million shs1.59 million shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+2.80%+4.29%-0.28%+1.33%-8.82%
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.25%-1.73%+6.76%+11.93%+36.71%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
+0.99%-3.35%-9.80%-1.23%-3.45%
Stryker Co. stock logo
SYK
Stryker
-0.43%-3.07%-6.52%-4.48%+13.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9284 of 5 stars
2.45.03.34.03.72.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.3622 of 5 stars
2.53.00.04.22.32.52.5
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
4.554 of 5 stars
2.35.00.04.02.62.52.5
Stryker Co. stock logo
SYK
Stryker
4.9561 of 5 stars
3.43.03.34.23.22.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0019.34% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
2.95
Moderate Buy$75.093.06% Upside
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
2.53
Moderate Buy$92.718.77% Upside
Stryker Co. stock logo
SYK
Stryker
2.78
Moderate Buy$365.9411.42% Upside

Current Analyst Ratings

Latest EW, BSX, BDX, and SYK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Stryker Co. stock logo
SYK
Stryker
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$372.00 ➝ $376.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$364.00 ➝ $381.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$348.00 ➝ $405.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$339.00 ➝ $351.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$375.00 ➝ $380.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$350.00 ➝ $375.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/1/2024
Stryker Co. stock logo
SYK
Stryker
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$367.00 ➝ $378.00
5/1/2024
Stryker Co. stock logo
SYK
Stryker
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$366.00 ➝ $369.00
4/26/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $78.00
4/26/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$94.00 ➝ $99.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.50$20.30 per share11.56$88.92 per share2.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
$14.71B7.43$2.93 per share24.87$13.33 per share5.47
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$6.00B8.55$2.79 per share30.51$11.93 per share7.15
Stryker Co. stock logo
SYK
Stryker
$20.96B5.96$13.42 per share24.47$50.39 per share6.52

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2255.6016.381.936.44%13.57%6.56%8/1/2024 (Estimated)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.1961.2327.812.4812.06%16.63%9.24%7/25/2024 (Estimated)
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$1.40B$2.3236.7427.413.5523.01%22.86%16.52%7/24/2024 (Estimated)
Stryker Co. stock logo
SYK
Stryker
$3.17B$8.7637.4924.622.6316.03%23.05%10.88%8/1/2024 (Estimated)

Latest EW, BSX, BDX, and SYK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q2 24
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.97$3.17+$0.20$4.49$5.04 billion$5.05 billion      
4/30/2024Q1 24
Stryker Co. stock logo
SYK
Stryker
$2.36$2.50+$0.14$2.95$5.10 billion$5.24 billion      
4/25/2024Q1 2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.64$0.66+$0.02$0.74$1.58 billion$1.60 billion    
2/6/2024Q4 23
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.64$0.64N/A$0.67$1.50 billion$1.53 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.62%+4.77%90.05%52 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
Stryker Co. stock logo
SYK
Stryker
$3.200.97%+9.00%36.53%31 Years

Latest EW, BSX, BDX, and SYK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$0.951.62%6/10/20246/10/20246/28/2024
2/7/2024
Stryker Co. stock logo
SYK
Stryker
Quarterly$0.800.93%3/27/20243/29/20244/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.32
0.82
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
0.08
3.75
2.67
Stryker Co. stock logo
SYK
Stryker
0.56
1.71
0.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
79.46%
Stryker Co. stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
1.29%
Stryker Co. stock logo
SYK
Stryker
5.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.50 billion1.49 billionOptionable
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
19,800602.60 million594.83 millionOptionable
Stryker Co. stock logo
SYK
Stryker
52,000380.47 million358.02 millionOptionable

EW, BSX, BDX, and SYK Headlines

SourceHeadline
Two Stryker Seniors Awarded Scholarships From Bryan Area FoundationTwo Stryker Seniors Awarded Scholarships From Bryan Area Foundation
thevillagereporter.com - May 3 at 4:24 PM
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook (SYK)Boston Scientific Bucks the Medtech Slow Down and Raises Outlook (SYK)
marketbeat.com - May 3 at 1:38 PM
Stryker Corporation Just Beat EPS By 6.2%: Heres What Analysts Think Will Happen NextStryker Corporation Just Beat EPS By 6.2%: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 3 at 11:19 AM
Stryker Co. (NYSE:SYK) Expected to Post Q3 2024 Earnings of $2.90 Per ShareStryker Co. (NYSE:SYK) Expected to Post Q3 2024 Earnings of $2.90 Per Share
marketbeat.com - May 3 at 9:16 AM
Stifel Nicolaus Keeps Their Buy Rating on Stryker (SYK)Stifel Nicolaus Keeps Their Buy Rating on Stryker (SYK)
markets.businessinsider.com - May 3 at 6:19 AM
UBS Group Increases Stryker (NYSE:SYK) Price Target to $351.00UBS Group Increases Stryker (NYSE:SYK) Price Target to $351.00
americanbankingnews.com - May 3 at 6:16 AM
Stryker (NYSE:SYK) PT Raised to $369.00Stryker (NYSE:SYK) PT Raised to $369.00
americanbankingnews.com - May 3 at 6:16 AM
Stryker (NYSE:SYK) PT Raised to $380.00Stryker (NYSE:SYK) PT Raised to $380.00
americanbankingnews.com - May 3 at 6:16 AM
Stryker (NYSE:SYK) PT Raised to $378.00 at Robert W. BairdStryker (NYSE:SYK) PT Raised to $378.00 at Robert W. Baird
americanbankingnews.com - May 3 at 6:16 AM
Stryker (NYSE:SYK) PT Raised to $375.00Stryker (NYSE:SYK) PT Raised to $375.00
americanbankingnews.com - May 3 at 6:16 AM
Stryker (NYSE:SYK) PT Raised to $381.00Stryker (NYSE:SYK) PT Raised to $381.00
americanbankingnews.com - May 3 at 5:32 AM
Stryker (NYSE:SYK) PT Raised to $405.00Stryker (NYSE:SYK) PT Raised to $405.00
americanbankingnews.com - May 3 at 5:32 AM
Q2 2024 EPS Estimates for Stryker Co. (NYSE:SYK) Increased by AnalystQ2 2024 EPS Estimates for Stryker Co. (NYSE:SYK) Increased by Analyst
americanbankingnews.com - May 3 at 2:02 AM
Stryker Co. (NYSE:SYK) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MAStryker Co. (NYSE:SYK) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA
marketbeat.com - May 2 at 9:52 PM
Benjamin F. Edwards & Company Inc. Acquires 112,754 Shares of Stryker Co. (NYSE:SYK)Benjamin F. Edwards & Company Inc. Acquires 112,754 Shares of Stryker Co. (NYSE:SYK)
marketbeat.com - May 2 at 5:44 PM
Barclays Increases Stryker (NYSE:SYK) Price Target to $376.00Barclays Increases Stryker (NYSE:SYK) Price Target to $376.00
marketbeat.com - May 2 at 3:38 PM
Stryker completes acquisition of mfPHDStryker completes acquisition of mfPHD
pharmiweb.com - May 2 at 8:50 AM
Stryker First Quarter 2024 Earnings: Beats ExpectationsStryker First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 2 at 8:50 AM
Stryker Co. (NYSE:SYK) Forecasted to Earn Q2 2024 Earnings of $2.91 Per ShareStryker Co. (NYSE:SYK) Forecasted to Earn Q2 2024 Earnings of $2.91 Per Share
marketbeat.com - May 2 at 7:49 AM
Stryker (NYSE:SYK) Receives "Hold" Rating from Needham & Company LLCStryker (NYSE:SYK) Receives "Hold" Rating from Needham & Company LLC
americanbankingnews.com - May 2 at 5:10 AM
Raymond James Financial Services Advisors Inc. Sells 8,409 Shares of Stryker Co. (NYSE:SYK)Raymond James Financial Services Advisors Inc. Sells 8,409 Shares of Stryker Co. (NYSE:SYK)
marketbeat.com - May 1 at 11:16 PM
Bank of America Securities Reaffirms Their Buy Rating on Stryker (SYK)Bank of America Securities Reaffirms Their Buy Rating on Stryker (SYK)
markets.businessinsider.com - May 1 at 3:19 PM
Stryker Skids On Light Knee Replacements; Analyst Blames Mis-ModelingStryker Skids On Light Knee Replacements; Analyst Blames Mis-Modeling
finance.yahoo.com - May 1 at 3:19 PM
Stryker (NYSE:SYK) Price Target Raised to $381.00Stryker (NYSE:SYK) Price Target Raised to $381.00
marketbeat.com - May 1 at 2:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Edwards Lifesciences logo

Edwards Lifesciences

NYSE:EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Stryker logo

Stryker

NYSE:SYK
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.